Compare SDRL & STOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SDRL | STOK |
|---|---|---|
| Founded | 2005 | 2014 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.9B |
| IPO Year | N/A | 2019 |
| Metric | SDRL | STOK |
|---|---|---|
| Price | $34.85 | $29.19 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 10 |
| Target Price | ★ $46.25 | $34.50 |
| AVG Volume (30 Days) | 768.1K | ★ 812.5K |
| Earning Date | 02-25-2026 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | 0.55 | ★ 0.68 |
| Revenue | ★ $1,307,000,000.00 | $205,632,000.00 |
| Revenue This Year | $8.52 | $430.24 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $63.31 | ★ $41.92 |
| Revenue Growth | N/A | ★ 1128.17 |
| 52 Week Low | $17.74 | $5.35 |
| 52 Week High | $38.43 | $38.69 |
| Indicator | SDRL | STOK |
|---|---|---|
| Relative Strength Index (RSI) | 57.07 | 41.86 |
| Support Level | $34.61 | $25.21 |
| Resistance Level | $36.25 | $31.70 |
| Average True Range (ATR) | 1.43 | 2.05 |
| MACD | 0.01 | -0.54 |
| Stochastic Oscillator | 48.19 | 32.81 |
Seadrill Ltd is an offshore drilling contractor company. The company is engaged in providing offshore drilling services to the oil and gas industry. The primary business of the company is the ownership and operation of drillships, semi-submersible rigs, and jack-up rigs for operations in shallow to ultra-deepwater areas in both benign and harsh environments. The geographical segments of the company are the United States, Brazil, Angola, Norway, Canada and others. The company derives maximum revenue from the United States.
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.